Company intelligence / Profile preview

Tikun Olam-Cannbit

Tel Aviv, Israel

Ownership: Private
Development stage: Other

Overview

Tikun Olam-Cannbit is Israel’s leading and pioneering provider of medical cannabis, supporting more than 30,000+ patients, with over 35 clinical and preclinical studies and broad global recognition for strain-specific, clinically validated cannabis products. The company recently received EU-GMP certification for its Israeli manufacturing/production site, enabling commercial export to Europe. Peer-reviewed results demonstrate efficacy for pain, neurological, and inflammatory indications.

Therapeutic areas: RheumatologyPsychiatryGastroenterologyOncologyNeurology
Modalities: Plant-derived therapySmall molecule (cannabinoid)Biologic (cannabinoid extract)
Industry: Biotech

Partnerships

Fette Pharma (Germany)Canonic (Evogene Group)

Beyond the preview

Go deeper on Tikun Olam-Cannbit.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tikun Olam-Cannbit.

Explore the full profile